We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expedited Programs Mean Better Drugs, But Firms Are Slow to Confirm Benefits
Expedited Programs Mean Better Drugs, But Firms Are Slow to Confirm Benefits
The FDA has largely succeeded in expediting the review of drugs with larger health gains, but postmarket trials by companies have fallen behind in confirming some of those benefits, with many not using the gold standard of randomized controlled trials, according to two independent studies.